Drug metabolism and personalized therapy最新文献

{"title":"Application of herbal liniment (<i>'Ṭilā</i>) in the management of pain and disability of chronic migraine: a randomized controlled trial.","authors":"Suresh Kumar Saral, Abdul Nasir Ansari, Mohd Nayab, Khalid Rahim Wani","doi":"10.1515/dmpt-2025-0079","DOIUrl":"10.1515/dmpt-2025-0079","url":null,"abstract":"<p><strong>Objectives: </strong>Chronic migraine is a prevalent and disabling neurological disorder affecting 1-3 % of the global population. Ancient Unani physicians have described herbal liniment (<i>'Ṭilā</i>) as a treatment modality for chronic migraine. This study aimed to evaluate its efficacy in managing the condition.</p><p><strong>Methods: </strong>A randomized controlled trial was conducted on 36 patients with chronic migraine. Participants were divided into two groups: the test group (n=24), which received herbal liniment applied locally once daily for 15 days, and the control group (n=12), which underwent transcutaneous electrical nerve stimulation (TENS) for 30 min daily, 5 days a week, over 2 weeks. Outcomes were measured using the Visual Analogue Scale (VAS), headache frequency, and the Migraine Disability Assessment Scale (MIDAS) on days 15, 30, 60, and 90.</p><p><strong>Results: </strong>Both groups showed significant improvement within the groups in headache frequency (p<0.0001). The test group demonstrated greater effectiveness, with larger reductions in headache frequency (mean difference 39.63; p<0.0001), VAS (mean difference 3.96; p<0.001), and MIDAS (mean difference 2.25; p=0.003).</p><p><strong>Conclusions: </strong>Herbal liniment effectively reduced migraine frequency, intensity, and disability. Larger studies are needed to validate these findings and assess long-term outcomes.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"21-28"},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From warfarin resistance to warfarin overdose: an unusual case report.","authors":"Mehmet Uğur Çalışkan","doi":"10.1515/dmpt-2025-0062","DOIUrl":"10.1515/dmpt-2025-0062","url":null,"abstract":"<p><strong>Objectives: </strong>Warfarin resistance represents a rare yet clinically significant challenge, especially among patients with mechanical heart valves. It may result from either hereditary or acquired factors.</p><p><strong>Case presentation: </strong>A 27-year-old male patient with a history of aortic and mitral valve replacement was followed with subtherapeutic International Normalized Ratio (INR) of 1.8-2.0 despite receiving 20 mg/day of warfarin. He was hospitalized for evaluation, and potential acquired causes of warfarin resistance were excluded. The patient was discharged with a plan for close INR monitoring. Following the initiation of lorazepam and olanzapine for a comorbid psychiatric condition, he re-presented with bleeding manifestations due to warfarin overdose. Notably, his apparent warfarin resistance resolved after the addition of these medications, and he has since been maintained within the therapeutic INR range on a stable warfarin dose of 5 mg/day.</p><p><strong>Conclusions: </strong>Warfarin is known to interact with numerous medications, and new drug interactions continue to be reported in the literature. Although no major interactions with lorazepam or olanzapine have been previously documented, in this case the concomitant initiation of these agents appeared to overcome warfarin resistance. This clinical course was remarkable for the apparent resolution of warfarin resistance, raising the possibility of underlying pharmacologic interactions.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"51-53"},"PeriodicalIF":0.0,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole genome circRNA profiling of <i>Withania somnifera</i> in human neuroblastoma SK-N-SH cells.","authors":"Anand Bhaskar, Dilip Mehta, Bhirisha Sharma, Jash Trivedi, Dhananya S, Manju Moorthy, Gopalakrishna Ramaswamy, Sujit Nair","doi":"10.1515/dmpt-2025-0064","DOIUrl":"10.1515/dmpt-2025-0064","url":null,"abstract":"<p><strong>Objectives: </strong>Defined by their unique covalently closed loop, circular RNAs (circRNAs) are a specific class of noncoding RNAs known for their stability and resilience against degradation. They act as microRNA sponges, transcriptional regulators, and modulators of protein interactions. <i>Withania somnifera</i> (WS), a prominent member of the Solanaceae family, is renowned for its anti-oxidative and neuroprotective properties. Although circRNAs are recognized as critical regulators in neurological disorders, their putative roles in eliciting the health-beneficial effects of WS, also known as Ashwagandha, are still unexplored.</p><p><strong>Methods: </strong>This study investigates WS-modulated global circRNA expression profiles in the SK-N-SH human neuroblastoma cell line, a widely used model for brain-related diseases. We conducted whole genome circRNA profiling using sequencing to identify differentially expressed circRNAs upon WS treatment.</p><p><strong>Results: </strong>A total of 26,489 circRNAs were detected, out of which 1,515 were novel. Dose-dependent and temporal differential gene expression analysis found 26 upregulated and 20 downregulated circRNAs which were linked to pathways relevant to neuroinflammation, synaptic plasticity and neuronal survival through functional and pathway enrichment analysis.</p><p><strong>Conclusions: </strong>This study sheds light on the regulatory roles of circRNAs in WS's therapeutic effects, suggesting that modulating circRNA expression may be a key mechanism by which it exerts its benefits. These findings open new avenues for WS-based therapeutic strategies for brain-related diseases, thereby highlighting the therapeutic utility of circRNAs in neurological contexts.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"9-20"},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring two medicinally important <i>Selinum</i> species: bridging traditional knowledge with modern pharmacological insights.","authors":"Ruchika Kumari, Palak Thakur, Vipasha Sharma, Ashun Chaudhary","doi":"10.1515/dmpt-2025-0043","DOIUrl":"10.1515/dmpt-2025-0043","url":null,"abstract":"<p><strong>Background: </strong><i>Selinum</i> is an important genus in the Apiaceae family, known for its essential oil-bearing medicinal properties. <i>Selinum vaginatum</i> C. B. Clarke and <i>Ligusticopsis wallichiana</i> (DC.) Pimenov & Kljuykov (Syn. <i>Selinum wallichianum</i> (DC.) Raizada & H. O. Saxena and <i>Selinum tenuifolium</i> Wall. ex DC.) are the two important species found in Himachal Pradesh, India.</p><p><strong>Content: </strong>The primary objective of this review is to present an updated report on the phytochemistry, traditional knowledge, and pharmacological profile of two species of the genus <i>Selinum</i> that are found in the Western Himalayas.</p><p><strong>Summary: </strong>The genus <i>Selinum</i> is commonly referred to as Bhutakeshi or Bhootkeshi. Strong evidence supports <i>Selinum</i>'s claims for its traditional ethnomedical importance and is used to treat cardiovascular diseases, asthma, toothache, mental disorders and diabetes. It is also used as an insect repellent and in magico-religious practices. The plant has antioxidant, anti-inflammatory, anticancer, anticonvulsant, and antimicrobial activities. The plant is rich in phenols, flavonoids, alkaloids, and terpenoids that contribute to its bioactivities.</p><p><strong>Outlook: </strong>This review outlines the important phytochemicals, traditional uses, and potential pharmacological properties of <i>Selinum</i> species. Further investigation is needed to elucidate the mechanistic importance of its bioactive components in drug development processes and to investigate the therapeutic potential at the clinical level.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"199-215"},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dr. José María Cantú Garza award.","authors":"Ingrid Fricke-Galindo, Adrián LLerena","doi":"10.1515/dmpt-2025-0086","DOIUrl":"10.1515/dmpt-2025-0086","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"197-198"},"PeriodicalIF":0.0,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacogenetic insights into <i>MTHFR</i> and <i>SLC19A1</i> variants in low-dose methotrexate therapy for rheumatologic diseases.","authors":"Goitybell Martínez Téllez, Beatriz Marcheco Teruel","doi":"10.1515/dmpt-2025-0047","DOIUrl":"10.1515/dmpt-2025-0047","url":null,"abstract":"<p><p>The identification of genetic markers that will enable accurate diagnosis and prediction of the therapy outcome is a crucial step in managing rheumatologic and autoimmune diseases. Low-dose methotrexate is a mainstay therapeutic agent for treatment. The objective of this review is to summarize the data on candidate single nucleotide polymorphisms in methylenetetrahydrofolate reductase (<i>MTHFR</i>) and solute carrier family 19 member 1 (<i>SLC19A1</i>) genes involved in methotrexate pathways. Over the past decade, several functional polymorphisms affecting methylenetetrahydrofolate reductase activity have been studied in the context of low-dose methotrexate therapy. The most frequently investigated polymorphisms are rs1801133 (c.665C>T) and rs1801131 (c.1286A>C) in <i>MTHFR</i> gene and rs1051266 (c.80A>G) in <i>SLC19A1</i> gene. Although the effects of these polymorphisms are remaining unclear, several studies have shown association with adverse effect while fewer studies have demonstrated association with remission or positive response to methotrexate. However, there is scarcity research in Latin American population assessing the influence of genetic variants in the pharmacokinetics and pharmacodynamics of methotrexate in the context of interethnic admixture. There is an urgent need of to expand these studies and to support the development of clinical pharmacogenomics guidelines.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"217-221"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of antimicrobial and immunomodulatory activities of Eugenol isolated from Syzygium aromaticum in a rat model.","authors":"Raghad Abdulsalam Khaleel, Zinah Essam Hameed, Omar Hussein Ahmed","doi":"10.1515/dmpt-2025-0035","DOIUrl":"10.1515/dmpt-2025-0035","url":null,"abstract":"<p><strong>Objectives: </strong>The increasing resistance of human infections to pharmaceutical treatments represents a critical global health challenge. Traditional herbs may complement modern antibacterial strategies. This study investigates the antimicrobial, antioxidant, and immunomodulatory properties of Eugenol extracted from <i>Syzygium aromaticum</i>.</p><p><strong>Methods: </strong>The essential oil was achieved through hydro distillation and analyzed using HPLC. Antioxidant capabilities were assessed using the DPPH radical scavenging assay and reducing power. MTT assays revealed the viability percentages of A549 and MRC5 cell lines after 48 h of exposure to methanolic extract and valerianic acid. Minimum inhibitory concentration (MIC) and broth microdilution methods were utilized to test antibiotic activity against <i>Staphylococcus aureus</i>, <i>Escherichia coli</i>, and <i>Candida albicans</i>. Finally, the essential oil (average concentration 13.1 % ± 0.23, with major components Eugenol, β-caryophyllene, and Eugenol Acetate) was orally administered to rats for 14 days. <i>In vivo</i> safety and immunomodulatory effects were assessed through histopathological, hematological, and hepatic enzyme analyses, as well as cytokine profiling.</p><p><strong>Results: </strong>The essential oil, rich in Eugenol, β-caryophyllene, and Eugenol acetate, demonstrated strong antioxidant activity. It exhibited significant antimicrobial effects at concentrations≥5 mg/mL, with inhibition zones comparable to standard antibiotics. Cytotoxicity remained low, and <i>in vivo</i> analysis revealed no adverse effects. The extract also increased IFN-γ and IL-4 levels, indicating immunomodulatory potential.</p><p><strong>Conclusions: </strong>The study indicated an immunomodulatory impact by increasing IFN-γ and IL-4 levels, with no negative effects on hepatic enzymes, hematological parameters, or histopathology. In summary, this research demonstrates that Eugenol, even at low concentrations, exhibits promising antioxidant and antimicrobial activities against common pathogens.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"249-261"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the attitude to pharmacogenomics testing among pharmacists in Iraq.","authors":"Yazun Bashir Jarrar, Dina Abu Hashem, Mariam Homsi, Abdulqader Fadhil Abed, Yasmeen Ibrahim","doi":"10.1515/dmpt-2025-0065","DOIUrl":"10.1515/dmpt-2025-0065","url":null,"abstract":"<p><strong>Objectives: </strong>Pharmacogenomics (PGx) testing optimizes drug efficacy and minimizes adverse effects, yet its implementation in Iraq remains limited. This study assessed Iraqi pharmacists' attitudes toward PGx testing to identify gaps in education and clinical readiness.</p><p><strong>Methods: </strong>A cross-sectional survey of 99 Iraqi pharmacists was conducted (June-August 2020). The 20-item questionnaire evaluated demographics, PGx education exposure, attitudes, and self-reported competence using a three-point Likert scale. Data were analyzed descriptively via SPSS.</p><p><strong>Results: </strong>Most participants were young (83 % aged 21-30), held bachelor's degrees (87.88 %), and supported PGx integration into curricula (80.81 %). While 95 % believed pharmacists should possess PGx knowledge, self-reported competency was low (35-54 %).</p><p><strong>Conclusions: </strong>Despite strong support for PGx, limited educational exposure and low confidence in applying PGx testing highlight the need for curriculum enhancements and targeted training programs in Iraq. Iraqi pharmacists recognize PGx's clinical value but require further education to bridge competence gaps. Policymakers should prioritize PGx training to facilitate implementation.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"243-248"},"PeriodicalIF":0.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145548725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neural network modelling of experimental diabetes to study new antidiabetic drugs.","authors":"Zhansulu Nurgaliyeva, Ayazhan Dauletkaliyeva, Serzhan Dauletkaliyev, Dana Tolegen, Rauza Romanova","doi":"10.1515/dmpt-2025-0049","DOIUrl":"10.1515/dmpt-2025-0049","url":null,"abstract":"<p><strong>Objectives: </strong>Diabetes mellitus is a complex metabolic disease characterised by chronic hyperglycaemia, which triggers a cascade of pathological changes in the body. Contemporary methods for developing antidiabetic drugs are often lengthy, expensive, and not always effective. The use of neural networks for modelling diabetes opens up new possibilities for accelerating research and increasing the accuracy of predicting the effectiveness of novel therapeutic strategies. The aim of this study was to develop and validate a neural network for studying experimental diabetes and assessing the efficacy of new antidiabetic drugs, as well as to explore the potential of combined therapeutic strategies.</p><p><strong>Methods: </strong>The empirical investigation was conducted using laboratory models of diabetes induced in rats with streptozotocin. Three groups were formed: a control group, a diabetic group without treatment, and a diabetic group treated with experimental drugs.</p><p><strong>Results: </strong>A neural network, based on multilayer perceptrons and recurrent architectures, was trained to predict changes in glucose levels, oxidative stress markers, and the condition of pancreatic tissues. The developed model demonstrated high predictive accuracy of metabolic changes, with an average accuracy of 92.3 %. As a result of treatment with experimental drugs, blood glucose levels in rats decreased by 25-30 % over 28 days, accompanied by a 26 % reduction in oxidative stress markers and partial restoration of pancreatic β-cell function in 30 % of cases. Histological analysis confirmed reduced fibrosis and improved tissue condition in the treatment group. The model also identified that combined therapeutic strategies - for example, the combination of antioxidants with gluconeogenesis inhibitors - had a synergistic effect, lowering glucose levels by up to 40 %.</p><p><strong>Conclusions: </strong>The study confirmed the effectiveness of the developed neural network for analysing therapeutic strategies and predicting metabolic changes in diabetes models. The proposed neural network represents a promising tool for investigating new antidiabetic drugs, including efficacy assessment within personalised medicine. Its application may accelerate preclinical research, optimise therapeutic approaches, and contribute to reducing drug development costs.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"231-241"},"PeriodicalIF":0.0,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of the c.557A>G variant for the implementation of <i>DPYD</i> pharmacogenetics in populations with Afro-Latin American ancestry.","authors":"Carla González de la Cruz, Fernanda Rodrigues-Soares, Mariela Guevara, Ernesto Rodríguez, Caíque Manóchio, Eva Peñas-Lledó, Pedro Dorado, Adrián LLerena","doi":"10.1515/dmpt-2025-0070","DOIUrl":"10.1515/dmpt-2025-0070","url":null,"abstract":"<p><p>Fluoropyrimidines are chemotherapy treatments widely used in chemotherapeutic regimens for different types of cancer. Adverse effects produced by dihydropyrimidine dehydrogenase (DPD) enzyme deficiency due to single nucleotide variants (SNVs) in the limiting enzyme of fluoropyrimidine catabolism occur with a high frequency in the world population; however, clinical recommendation guidelines focus mainly on variants of DPD gene (<i>DPYD</i>), which are highly prevalent in European populations. The aim of this review is to identify clinically relevant <i>DPYD</i> variants considering ethnic origin in order to develop population-specific genotyping panels for Afro-Latin Americans. Current recommendations from clinical guidelines and scientific literature in populations of African origin, including Dominican, have been reviewed. Based on the high reported frequency, the inclusion of the c.557A>G variant (which leads to a decrease in DPD enzyme activity) in populations of Afro-Latin American ancestry is proposed.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"3-8"},"PeriodicalIF":0.0,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}